Discover
MPLT
MapLight Therapeutics, Inc.
37.44
1 x 17.40
1 x 40.00
bid
ask
+
1.45
4.03%
93 @ 04:00 PM
38.64 +1.20 (3.21%)
| Ytd | 113.09% | |
| 1y | 104.14% |
36.03
day range
38.26
12.24
52 week range
40.43
| Open | 37.30 | Prev Close | 35.99 | Low | 36.03 | High | 38.26 | Mkt Cap | 29.55M |
| Vol | 557.56K | Avg Vol | 422.82K | EPS | -38.52 | P/E | -0.97 | Forward P/E | -10.51 |
| Beta | N/A | Short Ratio | 5.58 | Inst. Own | 56.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 31.66 | 200-d Avg | 22.78 | 1yr Est | 41.50 |
MPLT News
benzinga.com
Needham Maintains Buy on MapLight Therapeutics, Raises Price Target to $45
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the
benzinga.com
Raymond James Initiates Coverage On MapLight Therapeutics with Strong Buy Rating, Announces Price Ta
Raymond James analyst Tiago Fauth initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with
benzinga.com
Craig-Hallum Maintains Buy on MapLight Therapeutics, Lowers Price Target to $40
Craig-Hallum analyst Adam Vogel maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowe
benzinga.com
Needham Maintains Buy on MapLight Therapeutics, Raises Price Target to $42
Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the
benzinga.com
MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents
MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements
benzinga.com
MapLight Therapeutics Announces Topline Results From Its IRIS A Phase 2 Study Of ML-004 In Autism Sp
The study randomized 161 participants (102 adolescents, 59 adults), with prespecified analyses plann
benzinga.com
This Prudential Financial Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Wall Street analysts changed outlook on top names, including PRU, ARE, TRGP, VITL, and GOOGL. See an
benzinga.com
9 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
Earnings Scheduled For March 26, 2026